George Janossy
Research Subjects
Research Interests
George Janossy has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ilesh Vinodrai Jani
Instituto Nacional de Saúde
2 shared publications Arsene Bikoue
HIV Immunology, Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, London, United Kingdom,1 Department of Molecular Medicine and Hematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa2
1 shared publication- Arsene Bikoue
Department of Immunology and Molecular Pathology, Royal Free and University College Medical School, London, UK
1 shared publication - Christine Gwanzura
Department of Haematology, College of Health Sciences University of Zimbabwe, Harare, Zimbabwe
1 shared publication - David Barnett
UK NEQAS for Leucocyte Immunophenotyping, Department of Haematology, Royal Hallamshire Hospital, Sheffield, United Kingdom
1 shared publication - David Katzenstein
Department of Medicine, Stanford University, Stanford, CA, United States of America
1 shared publication
Latest Publications
- Open Access
- 20 April 2010
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 78B (3) , 183-187
Translational medicine as implementation science in the field of monitoring HIV and TB. New concepts emanating from resource‐poor countries
- 20 April 2010
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 78B (3) , 183-187
Open AccessTranslational medicine as implementation science in the field of monitoring HIV and TB. New concepts emanating from resource‐poor countries
- Open Access
- 12 March 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 74B (S1) , S1-S3
Diagnostics in the shadow of HIV epidemics
- 12 March 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 74B (S1) , S1-S3
Open AccessDiagnostics in the shadow of HIV epidemics
- Open Access
- 28 January 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 74B (S1) , S6-S10
Simplified cytometry for routine monitoring of infectious diseases
- 28 January 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 74B (S1) , S6-S10
Open AccessSimplified cytometry for routine monitoring of infectious diseases
- 15 January 2008
- Published by Wiley in Biotechnology Journal
- Vol. 3 (1) , 32-42
The changing pattern of “smart” flow cytometry (S‐FC) to assist the cost‐effective diagnosis of HIV, tuberculosis, and leukemias in resource‐restricted conditions
There is a need to introduce cytometry into areas of the globe that have remained virtually untouched by modern laboratory medicine. With the demand to carry out tests on 100 000s of individuals requiring antiretroviral therapy (ART), flow cytometry must remain simple and cost‐effective – while being sustainable and industry supported as well as proven by quality assessment (QA). This outlook is referred to as “smart flow cytometry” (S‐FC). There are five main areas where the power of S‐FC is demonstrated. These are: (i) the use of CD45 to assist precise cell counting in blood and tissue samples; (ii) the primary CD4 gating to count CD4+ T cells in patients waiting for ART, including the combination (i) and (ii) in the panleucogating (PLG) protocol; (iii) monitoring of human immunodeficiency virus (HIV+) patients during ART by the decreasing levels of lymphocyte activation in a CD8/CD38 test – leading to economies of viral‐load assays; (iv) in tuberculosis and HIV–TB coinfections the use of TB‐antigen‐stimulated cytokine‐synthetic CD4+ Tcells to identify active disease; and (v) the utilization of “minimal residual disease (MRD)‐Lite” technology in patients 19 days after the start of antileukemic therapy to detect MRD. These methods of S‐FC have been successfully introduced in “resource‐restricted” countries with international and local QA.
- 15 January 2008
- Published by Wiley in Biotechnology Journal
- Vol. 3 (1) , 32-42
The changing pattern of “smart” flow cytometry (S‐FC) to assist the cost‐effective diagnosis of HIV, tuberculosis, and leukemias in resource‐restricted conditions
There is a need to introduce cytometry into areas of the globe that have remained virtually untouched by modern laboratory medicine. With the demand to carry out tests on 100 000s of individuals requiring antiretroviral therapy (ART), flow cytometry must remain simple and cost‐effective – while being sustainable and industry supported as well as proven by quality assessment (QA). This outlook is referred to as “smart flow cytometry” (S‐FC). There are five main areas where the power of S‐FC is demonstrated. These are: (i) the use of CD45 to assist precise cell counting in blood and tissue samples; (ii) the primary CD4 gating to count CD4+ T cells in patients waiting for ART, including the combination (i) and (ii) in the panleucogating (PLG) protocol; (iii) monitoring of human immunodeficiency virus (HIV+) patients during ART by the decreasing levels of lymphocyte activation in a CD8/CD38 test – leading to economies of viral‐load assays; (iv) in tuberculosis and HIV–TB coinfections the use of TB‐antigen‐stimulated cytokine‐synthetic CD4+ Tcells to identify active disease; and (v) the utilization of “minimal residual disease (MRD)‐Lite” technology in patients 19 days after the start of antileukemic therapy to detect MRD. These methods of S‐FC have been successfully introduced in “resource‐restricted” countries with international and local QA.
- 1 January 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 74B (S1) , S141-S151
The role of flow cytometry in the interferon-γ-based diagnosis of active tuberculosis and its coinfection with HIV-1-A technically oriented review
TB remains uncontrolled. In resource‐rich countries, only ∼60% of diagnoses are confirmed by culture. The number is lower in resource‐poor environments. Huge scope therefore exists for alternative diagnostic strategies. Counting antigen‐specific lymphocytes by virtue of cytokine production following 8–16 h stimulation with tuberculosis antigens is currently the strategy of choice. Several methods exist, including ELISA, ELISpots, and flow cytometry. Although it is clear that blood samples stimulated by ESAT‐6 and CFP‐10 antigens discriminate between TB infection and BCG vaccination, it is flow‐cytometry that seems to be able to distinguish active TB disease from mere TB exposure. Of the various flow‐protocols including four‐color tests (CD45‐CD3‐CD4‐IFNγ), three‐color tests (CD3‐CD4‐IFNγ) and two‐color tests (CD4‐IFNγ), even the simplest is performing well, provided that the results are expressed as percentage of IFN‐γ+ cells per CD4+ lymphocytes (%IFNγ/CD4+). Studies using broncho‐alveloar lavage (BAL) and Induced‐Sputum (ISp) show that TB‐specific CD4+IFN‐γ+ T cells accumulate in the lung in pulmonary and extra‐pulmonary TB at frequencies >5–20‐fold more frequent than in blood. This pulmonary homing is absent following BCG immunization. The use of PPD to stimulate CD4+IFN‐γ+ cells in the lung in active TB leads to >3–12‐fold greater responses than seen with CFP‐10 or ESAT‐6, and any interference from BCG vaccination is absent. This method is unaffected by HIV coinfection, which has always been the problem for other immune‐based diagnostics. Further, lung‐based samples provide material for rapid tests of both the IFN‐γ assay and bacteriology, and importantly, these tests are amenable for future simplification with automated fluorescence‐image cytometers. Another development of the multiparameter analytical power of flow‐cytometry is to use markers for “lung‐seeking” populations of CD4+ T cells in blood, obviating lung sampling. In active TB, but not in BCG vaccinees, TB‐specific memory CD4+ T cells can be found in blood that are dominantly CD27‐negative and probably lung seeking and can be diagnostically useful. © 2007 Clinical Cytometry Society
- 1 January 2008
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 74B (S1) , S141-S151
The role of flow cytometry in the interferon-γ-based diagnosis of active tuberculosis and its coinfection with HIV-1-A technically oriented review
TB remains uncontrolled. In resource‐rich countries, only ∼60% of diagnoses are confirmed by culture. The number is lower in resource‐poor environments. Huge scope therefore exists for alternative diagnostic strategies. Counting antigen‐specific lymphocytes by virtue of cytokine production following 8–16 h stimulation with tuberculosis antigens is currently the strategy of choice. Several methods exist, including ELISA, ELISpots, and flow cytometry. Although it is clear that blood samples stimulated by ESAT‐6 and CFP‐10 antigens discriminate between TB infection and BCG vaccination, it is flow‐cytometry that seems to be able to distinguish active TB disease from mere TB exposure. Of the various flow‐protocols including four‐color tests (CD45‐CD3‐CD4‐IFNγ), three‐color tests (CD3‐CD4‐IFNγ) and two‐color tests (CD4‐IFNγ), even the simplest is performing well, provided that the results are expressed as percentage of IFN‐γ+ cells per CD4+ lymphocytes (%IFNγ/CD4+). Studies using broncho‐alveloar lavage (BAL) and Induced‐Sputum (ISp) show that TB‐specific CD4+IFN‐γ+ T cells accumulate in the lung in pulmonary and extra‐pulmonary TB at frequencies >5–20‐fold more frequent than in blood. This pulmonary homing is absent following BCG immunization. The use of PPD to stimulate CD4+IFN‐γ+ cells in the lung in active TB leads to >3–12‐fold greater responses than seen with CFP‐10 or ESAT‐6, and any interference from BCG vaccination is absent. This method is unaffected by HIV coinfection, which has always been the problem for other immune‐based diagnostics. Further, lung‐based samples provide material for rapid tests of both the IFN‐γ assay and bacteriology, and importantly, these tests are amenable for future simplification with automated fluorescence‐image cytometers. Another development of the multiparameter analytical power of flow‐cytometry is to use markers for “lung‐seeking” populations of CD4+ T cells in blood, obviating lung sampling. In active TB, but not in BCG vaccinees, TB‐specific memory CD4+ T cells can be found in blood that are dominantly CD27‐negative and probably lung seeking and can be diagnostically useful. © 2007 Clinical Cytometry Society
- Open Access
- 1 February 2005
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 3 (1) , 6
T lymphocytes among HIV-infected and -uninfected infants: CD4/CD8 ratio as a potential tool in diagnosis of infection in infants under the age of 2 years
Background: Serologic tests for HIV infection in infants less than 18 months do not differentiate exposure and infection since maternally acquired IgG antibodies may be detected in infants. Thus, the gold standard for diagnosis of HIV-1 infection in infants under the age of 2 years is DNA or reverse transcriptase polymerase chain reaction. There is an urgent need to evaluate alternative and cost effective laboratory methods for early diagnosis of infant HIV-1 infection as well as identifying infected infants who may benefit from cotrimoxazole prophylaxis and/or initiation of highly active antiretroviral therapy. Methods: Whole blood was collected in EDTA from 137 infants aged 0 to 18 months. DNA polymerase chain reaction was used as the reference standard for diagnosis of HIV-1 infection. T-cell subset profiles were determined by flow cytometry. Results: Seventy-six infants were DNA PCR positive while 61 were negative. The median CD4 counts of PCR negative infants were significantly higher than those of the PCR positive infants, p < 0.001. The median CD4/CD8 ratio and the %CD4 of the PCR positive infants were both significantly lower than those of the negative infants, p < 0.001. The CD4/CD8 ratio had a >98% sensitivity for diagnosis of HIV-1 infection and a specificity of >98%. Conclusion: The CD4/CD8 ratio appears useful in identifying HIV-infected infants. The development of lower cost and more robust flow cytometric methods that provide both CD4/CD8 ratio and %CD4 may be cost-effective for HIV-1 diagnosis and identification of infants for cotrimoxazole prophylaxis and/or highly active antiretroviral therapy.
- 1 February 2005
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 3 (1) , 6
Open AccessT lymphocytes among HIV-infected and -uninfected infants: CD4/CD8 ratio as a potential tool in diagnosis of infection in infants under the age of 2 years
Background: Serologic tests for HIV infection in infants less than 18 months do not differentiate exposure and infection since maternally acquired IgG antibodies may be detected in infants. Thus, the gold standard for diagnosis of HIV-1 infection in infants under the age of 2 years is DNA or reverse transcriptase polymerase chain reaction. There is an urgent need to evaluate alternative and cost effective laboratory methods for early diagnosis of infant HIV-1 infection as well as identifying infected infants who may benefit from cotrimoxazole prophylaxis and/or initiation of highly active antiretroviral therapy. Methods: Whole blood was collected in EDTA from 137 infants aged 0 to 18 months. DNA polymerase chain reaction was used as the reference standard for diagnosis of HIV-1 infection. T-cell subset profiles were determined by flow cytometry. Results: Seventy-six infants were DNA PCR positive while 61 were negative. The median CD4 counts of PCR negative infants were significantly higher than those of the PCR positive infants, p < 0.001. The median CD4/CD8 ratio and the %CD4 of the PCR positive infants were both significantly lower than those of the negative infants, p < 0.001. The CD4/CD8 ratio had a >98% sensitivity for diagnosis of HIV-1 infection and a specificity of >98%. Conclusion: The CD4/CD8 ratio appears useful in identifying HIV-infected infants. The development of lower cost and more robust flow cytometric methods that provide both CD4/CD8 ratio and %CD4 may be cost-effective for HIV-1 diagnosis and identification of infants for cotrimoxazole prophylaxis and/or highly active antiretroviral therapy.
- Open Access
- 1 September 2002
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 9 (5) , 1085-1094
Affordable CD4 + -T-Cell Counting by Flow Cytometry: CD45 Gating for Volumetric Analysis
The flow cytometers that are currently supported by industry provide accurate CD4 + -T-cell counts for monitoring human immunodeficiency virus disease but remain unaffordable for routine service work under resource-poor conditions. We therefore combined volumetric flow cytometry (measuring absolute lymphocyte counts in unit volumes of blood) and simpler protocols with generic monoclonal antibodies (MAbs) to increase cost efficiency. Volumetric absolute counts were generated using CD45/CD4 and CD45/CD8 MAb combinations in two parallel tubes. The percentage values for the various subsets were also determined within the leukocyte and lymphocyte populations utilizing a fully automated protocol. The levels of agreement between the newly developed method and the present industry standards, including both volumetric and bead-based systems using a full MAb panel for subset analysis, were tested by Bland-Altman analyses. The limits of agreement for CD4 counts generated by the volumetric methods using either CD45/CD4 (in a single tube) or the full Trio MAb panel (in three tubes) on the CytoronAbsolute flow cytometer were between −29 and +46 cells/mm 3 with very little bias for CD4 counts (in favor of the Trio method: +8 CD4 + lymphocytes/mm 3 ; 0.38% of lymphocytes). The limits of agreement for absolute CD4 counts yielded by the volumetric CD45/CD4 method and the bead-based method were between −118 and +98 cells/mm 3 , again with a negligible bias (−10 CD4 + lymphocytes/mm 3 ). In the volumetric method using CD45/CD8, the strongly CD8 + cells were gated and the levels of agreement with the full Trio showed a minor bias (in favor of the Trio; +40 CD8 + cells/mm 3 ; 5.2% of lymphocytes) without a significant influence on CD4/CD8 ratios. One trained flow cytometrist was able to process 300 to 400 stained tubes per day. This workload extrapolates to a throughput of >30,000 samples per year if both CD45/CD4 and CD45/CD8 stainings are performed for each patient or a throughput of >60,000 samples if only CD45/CD4 counts are tested in a single tube. Thus, on the basis of the high efficiency and excellent agreement with the present industry standards, volumetric flow cytometers with automated gating protocols and autobiosamplers, complemented by generic CD45, CD4, and CD8 MAbs used in two-color immunofluorescence, represent the most suitable arrangements for large regional laboratories in resource-poor settings.
- 1 September 2002
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 9 (5) , 1085-1094
Open AccessAffordable CD4 + -T-Cell Counting by Flow Cytometry: CD45 Gating for Volumetric Analysis
The flow cytometers that are currently supported by industry provide accurate CD4 + -T-cell counts for monitoring human immunodeficiency virus disease but remain unaffordable for routine service work under resource-poor conditions. We therefore combined volumetric flow cytometry (measuring absolute lymphocyte counts in unit volumes of blood) and simpler protocols with generic monoclonal antibodies (MAbs) to increase cost efficiency. Volumetric absolute counts were generated using CD45/CD4 and CD45/CD8 MAb combinations in two parallel tubes. The percentage values for the various subsets were also determined within the leukocyte and lymphocyte populations utilizing a fully automated protocol. The levels of agreement between the newly developed method and the present industry standards, including both volumetric and bead-based systems using a full MAb panel for subset analysis, were tested by Bland-Altman analyses. The limits of agreement for CD4 counts generated by the volumetric methods using either CD45/CD4 (in a single tube) or the full Trio MAb panel (in three tubes) on the CytoronAbsolute flow cytometer were between −29 and +46 cells/mm 3 with very little bias for CD4 counts (in favor of the Trio method: +8 CD4 + lymphocytes/mm 3 ; 0.38% of lymphocytes). The limits of agreement for absolute CD4 counts yielded by the volumetric CD45/CD4 method and the bead-based method were between −118 and +98 cells/mm 3 , again with a negligible bias (−10 CD4 + lymphocytes/mm 3 ). In the volumetric method using CD45/CD8, the strongly CD8 + cells were gated and the levels of agreement with the full Trio showed a minor bias (in favor of the Trio; +40 CD8 + cells/mm 3 ; 5.2% of lymphocytes) without a significant influence on CD4/CD8 ratios. One trained flow cytometrist was able to process 300 to 400 stained tubes per day. This workload extrapolates to a throughput of >30,000 samples per year if both CD45/CD4 and CD45/CD8 stainings are performed for each patient or a throughput of >60,000 samples if only CD45/CD4 counts are tested in a single tube. Thus, on the basis of the high efficiency and excellent agreement with the present industry standards, volumetric flow cytometers with automated gating protocols and autobiosamplers, complemented by generic CD45, CD4, and CD8 MAbs used in two-color immunofluorescence, represent the most suitable arrangements for large regional laboratories in resource-poor settings.
- 1 December 2000
- Published by Wiley in British Journal of Haematology
- Vol. 111 (4) , 1198-1208
Affordable CD4+ T-cell counts on 'single-platform' flow cytometers I. Primary CD4 gating
Here, we demonstrate the flow cytometric concept of 'primary CD4 gating' utilizing three different CD4 monoclonal antibodies (mAbs) conjugated with five different fluorochromes. CD4(+) lymphocytes were defined by an autogate in a single histogram of CD4 fluorescence intensity (FI) (y-axis) vs. side light scatter (x-axis). A wide range of absolute counts for > 600 individuals, including HIV(+) patients, were compared with those obtained by 'state-of-the-art' single-platform flow cytometers such as the volumetric Ortho CytoronAbsolute and the Becton Dickinson FACSCalibur using TruCount beads. The correlation between CD4 counts obtained with primary CD4 gating and the full test panel on the Ortho Cytoron was excellent (R(2) = 0.999). Bland-Altman statistics showed a mean difference of -2 cells/mm(3) [confidence interval (CI) 95% = -3 to -1; limits of agreement -27 to +23]. In addition to absolute CD4 counts, CD4% values and CD4/CD8 ratios are also frequently requested. To obtain these, lymphocytes need to be counted using scatter gates, and a second tube stained with a CD8 mAb to count CD8(++) lymphocytes can be incorporated. We conclude that primary CD4 gating on single-platform volumetric flow cytometers is one of the most economical and flexible technologies for routine cost-conscious service work, particularly during the follow-up of patients undergoing anti-HIV therapy and/or vaccination in the developing world.
- 1 December 2000
- Published by Wiley in British Journal of Haematology
- Vol. 111 (4) , 1198-1208
Affordable CD4+ T-cell counts on 'single-platform' flow cytometers I. Primary CD4 gating
Here, we demonstrate the flow cytometric concept of 'primary CD4 gating' utilizing three different CD4 monoclonal antibodies (mAbs) conjugated with five different fluorochromes. CD4(+) lymphocytes were defined by an autogate in a single histogram of CD4 fluorescence intensity (FI) (y-axis) vs. side light scatter (x-axis). A wide range of absolute counts for > 600 individuals, including HIV(+) patients, were compared with those obtained by 'state-of-the-art' single-platform flow cytometers such as the volumetric Ortho CytoronAbsolute and the Becton Dickinson FACSCalibur using TruCount beads. The correlation between CD4 counts obtained with primary CD4 gating and the full test panel on the Ortho Cytoron was excellent (R(2) = 0.999). Bland-Altman statistics showed a mean difference of -2 cells/mm(3) [confidence interval (CI) 95% = -3 to -1; limits of agreement -27 to +23]. In addition to absolute CD4 counts, CD4% values and CD4/CD8 ratios are also frequently requested. To obtain these, lymphocytes need to be counted using scatter gates, and a second tube stained with a CD8 mAb to count CD8(++) lymphocytes can be incorporated. We conclude that primary CD4 gating on single-platform volumetric flow cytometers is one of the most economical and flexible technologies for routine cost-conscious service work, particularly during the follow-up of patients undergoing anti-HIV therapy and/or vaccination in the developing world.